SCHEMBL14019657

SCHEMBL14019657

CC(=O)c1cn(N(C)C)c2ccc(CCC=O)cc2c1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.34
ATM Q13315 1/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 1/20 0.33
LMNA P02545 3/20 0.33
SLC6A2 P23975 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HTT P42858 1/20 0.33
GAA P10253 1/20 0.33
RECQL P46063 1/20 0.33
CNR2 P34972 1/20 0.33
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
MAPT P10636 4/20 0.32
S1PR1 P21453 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3294020 0.86 LMNA (0.47) MEN1KMT2AALDH1A1HPGDLMNA
SCHEMBL14019666 0.84 CNR2 (0.42) RXFP1SLC6A2CNR2S1PR1
SCHEMBL14019665 0.84 TOP1 (0.38) RXFP1ATMMEN1KMT2AALDH1A1
SCHEMBL14019671 0.83 BRD4 (0.31)
SCHEMBL14019662 0.75 XDH (0.36) ALDH1A1HPGDLMNAKDM4EHTT
SCHEMBL4030026 0.75 KDM4E (0.42) ALDH1A1HPGDLMNAKDM4EHTT
SCHEMBL14019664 0.74 NPC1 (0.32) ATMMEN1KMT2AALDH1A1HPGD
SCHEMBL14019661 0.74 CNR2 (0.35) ATMALDH1A1HPGDLMNASLC6A2
SCHEMBL13799088 0.74 KDM4E (0.42) ALDH1A1HPGDLMNAKDM4EHTT
SCHEMBL1132860 0.72 LMNA (0.46) RXFP1MEN1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269146-A1 4''-Substituted Erythromycin Derivative GLAXO GROUP LIMITED 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269146-A1 4''-Substituted Erythromycin Derivative MRPL21, CYP3A4, CYP51A1 RXFP1 2725/4885ATM 4655/4885MEN1 4432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.